PT -期刊文章盟Burcu Zeydan AU -伊丽莎白·阿特金森AU -史密斯Carin盟-莉莉安娜Gazzuola罗卡AU -沃尔特·罗卡盟马克Keegan AU -布莱恩Weinshenker盟Kejal Kantarci AU - Orhun Kantarci TI -未产妇与女性进行性多发性硬化的早期进化(4887)DP - 2020年4月14日TA -神经病学PG - 4887 VI - 94 IP - 15补充4099 - //www.ez-admanager.com/content/94/15_Supplement/4887.short 4100 - //www.ez-admanager.com/content/94/15_Supple首页ment/4887.full所以Neurology2020 4月14日;94 AB -目的:调查协会的怀孕状况与年龄发病进展型多发性硬化症(MS)。背景:女性性是最重要的风险因素然而女士怀孕状态的进化进步协会女士并没有得到充分的研究。设计/方法:累进女士临床系列(n = 202, 134名妇女、68人)进行了研究。怀孕(奇偶校验/ para:怀孕数量达到可行的孕龄)和时代进步的发病和复发缓和女士女士(名RRMS)进行评估。结果:未生育过的妇女(n = 32)早些时候曾进步女士(PMS)发病比女性(41.4±12.6岁)≥1平价(n = 95;47.1±9.7岁)(p = 0.012)。PMS发病年龄也增加了平价量趋势(para 0: 41.4±12.6年,帕拉1 - 3:46.4±9.2年,para≥4: 52.6±12.9岁)(p = 0.002)。在二级进步女士(spm)只有子群,未生育过的女性早前spm发病年龄(n = 19;41.5±9.2岁)比女性≥1平价(n = 57;47.3±10.6岁)(p = 0.049)。名RRMS发病年龄也早在相同的未生育过的分组(27.5±7.0岁)比女性≥1平价(33.0±9.4岁)(p = 0.021)。 Dose effect trends were again observed by parity for age at SPMS onset (para 0: 41.5±9.2 yrs, para 1–3: 46.2±9.9 yrs, para ≥4: 52.6±12.9 yrs) (p=0.010) and age at RRMS onset (para 0: 27.5±7.0 yrs, para 1–3: 32.4±9.3 yrs, para ≥4: 35.8±9.8 yrs) (p=0.012).Conclusions: Nulliparity seems to be associated with earlier evolution to progressive MS. There is further need for a larger study to understand whether pregnancy related factors lead to earlier development of progressive MS, or whether MS-associated factors lead to nulliparity either by choice or due to biological reasons.Disclosure: Dr. Zeydan has nothing to disclose. Dr. Atkinson has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Gazzuola Rocca has nothing to disclose. Dr. Rocca has nothing to disclose. Dr. Keegan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Publishing royalties from Cambridge University Press for “Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases”. Dr. Keegan has received research support from Biogen. Dr. Weinshenker has received personal compensation from Alexion, Chugai/Roche, MedImmune, Mitsubishi Tanabe Pharma, Viela Bio. Dr Weinshenker has received research support from Alexion Pharmaceuticals, Terumo BCT.Dr. Kantarci has nothing to disclose. Dr. Kantarci has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis and Biogen. Dr. Kantarci has received research support from Biogen, the Multiple Sclerosis Society, the Mayo Foundation, and the Hilton Foundation.